Human PD-L1 antibodies and methods of use therefor
US12325747B2 · kind B2 · utility
0Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2022 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Nov 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.